No Data
With 64% Institutional Ownership, Regulus Therapeutics Inc. (NASDAQ:RGLS) Is a Favorite Amongst the Big Guns
JonesTrading Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $8
Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences
Oppenheimer Maintains Regulus Therapeutics(RGLS.US) With Buy Rating, Maintains Target Price $7
Regulus Therapeutics Poised for Growth: Promising ADPKD Study Results and Strategic Milestones Drive Buy Rating
Buy Rating for Regulus Therapeutics Driven by Promising Clinical and Regulatory Prospects for RGLS8429
No Data
AddiBee0925 : Hey Jag. Just a heads up. If all goes as planned, the launch for SIDU and SpaceX is on the schedule for this Friday on the 20th. I wouldn't think that it would be rescheduled so soon to the launch, at least no report has said otherwise.
Jaguar8 OP AddiBee0925 : Yes. But there might be a build up of the price before the launch just like LUNR. Hopefully it goes well.
AddiBee0925 Jaguar8 OP : yeah I'm thinking the same
Jaguar8 OP browny_440 : TNXP will be good if FDA releases decision soon
72306783 : I would like to ask, what signals or standards do you use to start building positions? I am still learning... Thank you very much for your Share
View more comments...